en Original Research <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:">Aims:</span></span></b><span style="background:white"><span cambria="" style="font-family:"> Despite many developments in the health care of cardiac surgery patients, yet 5%&ndash;30% of them may become challenged due to renal dysfunction, delirium, and arrhythmia. Eliminating or reducing these unwanted outcomes is likely to improve the prognosis of them. The purpose of the current study was to investigate the outcome of the administration of DEX in patients undergoing cardiac surgeries.</span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:">Materials & Methods:</span></span></b><span style="background:white"><span cambria="" style="font-family:"> The data from patents who underwent coronary artery bypass grafting (CABG) without a valve, CABG with valve surgery, and valve-only surgery from August to November 2018 were analyzed. A total of 51 patients were eligible for our study after extraction. For the DEX group, the infusion of DEX was started 10 min before anesthesia induction in a 0.2&ndash;0.6 &micro;g/Kg/h rate. And the same amount of normal saline (0.9%) was infused for the control group. The infusion was continued post-operatively until extubation (maximum for 24h). The patients were compared primarily for Acute Kidney Injury (AKI), delirium, new-onset atrial fibrillation (AF) rhythm.</span></span><span style="background:white"><span style="font-family:"Cambria",serif"></span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:">Findings:</span></span></b><span style="background:white"><span cambria="" style="font-family:"> There was no significant difference between groups for demographic data. One patient (16.7%) from the DEX group and five patients (83.3%) from the control group revealed an AF rhythm after surgery (p=0.009). No patient faced delirium. Seven patients seemed to be AKI, of which five (71.4%) were in the DEX group and two (28.6%) were in the control group (p>0.05).</span></span><span style="background:white"><span style="font-family:"Cambria",serif"></span></span></span></span></span><br> <span style="font-size:10pt"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><b><span style="background:white"><span cambria="" style="font-family:">Conclusion:</span></span></b><span style="background:white"><span cambria="" style="font-family:"> There might be a meaningful reduction of new-onset AF rhythm in adult patients who use DEX after cardiac surgeries.</span></span></span></span></span><br> &nbsp; Dexmedetomidine, Cardiac-Surgery, Atrial-Fibrillation 109 114 http://gmedicine.de/browse.php?a_code=A-10-1-36&slc_lang=en&sid=2 Sh. Sharifi 10031947532846001356 10031947532846001356 No National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran K. Saberi 10031947532846001357 10031947532846001357 Yes Imam Khomeini Medical and Research Centre, Tehran University of Medical Sciences, Tehran, Iran M. Rahmanian 10031947532846001358 10031947532846001358 No Imam Khomeini Medical and Research Centre, Tehran University of Medical Sciences, Tehran, Iran A. Bakhshandeh 10031947532846001359 10031947532846001359 No Imam Khomeini Medical and Research Centre, Tehran University of Medical Sciences, Tehran, Iran